Biology Reference
In-Depth Information
39. Escartin C, Brouillet E, Gubellini P, Trioulier
Y, Jacquard C, Smadja C, Knott GW,
Kerkerian-Le Goff L, Deglon N, Hantraye P,
Bonvento G (2006) Ciliary neurotrophic fac-
tor activates astrocytes, redistributes their glu-
tamate transporters GLAST and GLT-1 to
raft microdomains, and improves glutamate
handling in vivo. J Neurosci 26:5978-5989
40. Escartin C, Pierre K, Colin A, Brouillet E,
Delzescaux T, Guillermier M, Dhenain M,
Deglon N, Hantraye P, Pellerin L, Bonvento
G (2007) Activation of astrocytes by CNTF
induces metabolic plasticity and increases
resistance to metabolic insults. J Neurosci
27:7094-7104
41. Beurrier C, Faideau M, Bennouar KE,
Escartin C, Kerkerian-Le Goff L, Bonvento
G, Gubellini P (2010) Ciliary neurotrophic
factor protects striatal neurons against excito-
toxicity by enhancing glial glutamate uptake.
PLoS One 5:e8550
42. Perrin V, Regulier E, Abbas-Terki T, Hassig
R, Brouillet E, Aebischer P, Luthi-Carter R,
Deglon N (2007) Neuroprotection by
Hsp104 and Hsp27 in lentiviral-based rat
models of Huntington's disease. Mol Ther
15:903-911
43. Perrin V, Dufour N, Raoul C, Hassig R,
Brouillet E, Aebischer P, Luthi-Carter R,
Deglon N (2009) Implication of the JNK
pathway in a rat model of Huntington's dis-
ease. Exp Neurol 215:191-200
44. Franich NR, Fitzsimons HL, Fong DM,
Klugmann M, During MJ, Young D (2008)
AAV vector-mediated RNAi of mutant hun-
tingtin expression is neuroprotective in a
novel genetic rat model of Huntington's dis-
ease. Mol Ther 16:947-956
45. Boudreau RL, McBride JL, Martins I, Shen S,
Xing Y, Carter BJ, Davidson BL (2009)
Nonallele-specifi c silencing of mutant and
wild-type huntingtin demonstrates therapeu-
tic effi cacy in Huntington's disease mice. Mol
Ther 17:1053-1063
46. Drouet V, Perrin V, Hassig R, Dufour N,
Auregan G, Alves S, Bonvento G, Brouillet E,
Luthi-Carter R, Hantraye P, Deglon N (2009)
Sustained effects of nonallele-specifi c
Huntingtin silencing. Ann Neurol 65:276-285
47. Pfi ster EL, Kennington L, Straubhaar J, Wagh
S, Liu W, DiFiglia M, Landwehrmeyer B,
Vonsattel JP, Zamore PD, Aronin N (2009)
Five siRNAs targeting three SNPs may provide
therapy for three-quarters of Huntington's
disease patients. Curr Biol 19:774-778
48. Lunkes A, Lindenberg KS, Ben-Haiem L,
Weber C, Devys D, Landwehrmeyer GB,
Mandel JL, Trottier Y (2002) Proteases acting
on mutant huntingtin generate cleaved prod-
ucts that differentially build up cytoplasmic
and nuclear inclusions. Mol Cell 10:259-269
49. Dull T, Zufferey R, Kelly M, Mandel RJ,
Nguyen M, Trono D, Naldini L (1998) A
third-generation lentivirus vector with a
conditional packaging system. J Virol 72:
8463-8471
50. Zufferey R, Dull T, Mandel RJ, Bukovsky A,
Quiroz D, Naldini L, Trono D (1998) Self-
inactivating lentivirus vector for safe and effi -
cient in vivo gene delivery. J Virol
72:9873-9880
51. Wu X, Wakefi eld JK, Liu H, Xiao H, Kralovics
R, Prchal JT, Kappes JC (2000) Development
of a novel trans-lentiviral vector that affords
predictable safety. Mol Ther 2:47-55
52. Watson DJ, Kobinger GP, Passini MA, Wilson
JM, Wolfe JH (2002) Targeted transduction
patterns in the mouse brain by lentivirus vec-
tors pseudotyped with VSV, Ebola, Mokola,
LCMV, or MuLV envelope proteins. Mol
Ther 5:528-537
53. Wong LF, Azzouz M, Walmsley LE, Askham
Z, Wilkes FJ, Mitrophanous KA, Kingsman
SM, Mazarakis ND (2004) Transduction pat-
terns of pseudotyped lentiviral vectors in the
nervous system. Mol Ther 9:101-111
54. Liehl B, Hlavaty J, Moldzio R, Tonar Z,
Unger H, Salmons B, Gunzburg WH, Renner
M (2007) Simian immunodefi ciency virus
vector pseudotypes differ in transduction effi -
ciency and target cell specifi city in brain. Gene
Ther 14:1330-1343
55. Pertusa M, Garcia-Matas S, Mammeri H,
Adell A, Rodrigo T, Mallet J, Cristofol R,
Sarkis C, Sanfeliu C (2008) Expression of
GDNF transgene in astrocytes improves cog-
nitive defi cits in aged rats. Neurobiol Aging
29:1366-1379
56. Federici T, Kutner R, Zhang XY, Kuroda H,
Tordo N, Boulis NM, Reiser J (2009)
Comparative analysis of HIV-1-based lentivi-
ral vectors bearing lyssavirus glycoproteins
for neuronal gene transfer. Genet Vaccines
Ther 7:1
57. Mamber C, Verhaagen J, Hol EM (2010) In
vivo targeting of subventricular zone astro-
cytes. Prog Neurobiol 92:19-32
58. Mazarakis ND, Azzouz M, Rohll JB, Ellard
FM, Wilkes FJ, Olsen AL, Carter EE, Barber
RD, Baban DF, Kingsman SM, Kingsman AJ,
O'Malley K, Mitrophanous KA (2001) Rabies
virus glycoprotein pseudotyping of lentiviral
vectors enables retrograde axonal transport
and access to the nervous system after periph-
eral delivery. Hum Mol Genet 10:2109-2121
59. Kang Y, Stein CS, Heth JA, Sinn PL, Penisten
AK, Staber PD, Ratliff KL, Shen H, Barker
CK, Martins I, Sharkey CM, Sanders DA,
McCray PB Jr, Davidson BL (2002) In vivo
gene transfer using a nonprimate lentiviral
vector pseudotyped with Ross River Virus
glycoproteins. J Virol 76:9378-9388
Search WWH ::
Custom Search